Onconova Therapeutics, Inc. (NASDAQ:ONTX) enjoyed a 14.74% run-up in share price since hitting record low of $0.95. The stock managed 9% rise and now stands at $1.09 as of 02/13/2018. At recent session, the prices were hovering between $1.01 and $1.1. This company shares are 542.2% off its target price of $7 and the current market capitalization stands at $12.19M. The recent change has given its price a -26.91% deficit over SMA 50 and -71.91% deficit over its 52-week high. The stock witnessed -40.44% declines, -29.22% declines and -42.93% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ONTX’s volatility during a week at 12.49% and during a month it has been found around 13.26%.Onconova Therapeutics, Inc. (ONTX) Top Holders
Institutional investors currently hold around $3 million or 22.9% in ONTX stock. Look at its top three institutional owners. Tyndall Capital Partners L P owns $997 thousand in Onconova Therapeutics, Inc., which represents roughly 8.18% of the company’s market cap and approximately 33.23% of the institutional ownership. Similar statistics are true for the second largest owner, Sabby Management, Llc, which owns 840,960 shares of the stock are valued at $841 thousand. The third largest holder is 683 Capital Management, Llc, which currently holds $375 thousand worth of this stock and that ownership represents nearly 3.08% of its market capitalization.
At the end of 09/30/2017 reporting period, 11 institutional holders increased their position in Onconova Therapeutics, Inc. (NASDAQ:ONTX) by some 160,548 shares, 5 decreased positions by 100,241 and 2 held positions by 2,472,159. That puts total institutional holdings at 2,732,948 shares, according to SEC filings. The stock grabbed 4 new institutional investments totaling 12,921 shares while 1 institutional investors sold out their entire positions totaling 16,700 shares.Onconova Therapeutics, Inc. (NASDAQ:ONTX) Insider Trades
Multiple company employees have indulged in significant insider trading. Onconova Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Tyndall Capital Partners L P has acquired 1,100,000 shares of Onconova Therapeutics, Inc. (ONTX) in trading session dated Feb. 08, 2018. These shares are worth $1,111,000 and were traded at $1.01 each. The SEC filing shows that 683 Capital Management, Llc performed a purchase of 200,000 shares. The 10% Owner added these shares by way of transaction on Feb. 08, 2018. The company’s shares were assimilated at $1.04 per share worth to an investment of some $208,000 on account of 683 Capital Management, Llc.
President and CEO, Kumar Ramesh, purchased 23,810 common shares of Onconova Therapeutics, Inc. (ONTX) in the open market. In a transaction dated Apr. 26, 2017, the shares were bought at an average price of $2.1, giving away a sum of $50,001. After this purchase, 102,227 common shares of ONTX are directly owned by the insider, with total stake valued at $111,427.
In the transaction dated Apr. 26, 2017, the great number of shares acquired came courtesy the Director; Reddy E Premkumar added a total of 119,048 shares at an average price of $2.1, amounting to approximately $250,001. The insider now directly owns 385,832 shares worth $420,557.Onconova Therapeutics, Inc. (ONTX) Analyst Guide
Several analysts have released their opinion on Onconova Therapeutics, Inc. (NASDAQ:ONTX), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation.